Basel, 13 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that its Elecsys® Neurofilament Light Chain (NfL) test has received CE mark approval for the detection of neuroinflammation in patients diagnosed with relapsing remitting multiple sclerosis (RRMS). The test brings meaningful innovation to MS disease management, offering clinicians a minimally invasive way to monitor the biological damage caused by multiple sclerosis. Using a simple blood test to measure NfL – a protein released during ...

In today's trade, shares of Maruti Suzuki, Sun Pharma, TCS, LIC Shares of LIC will be in focus today as the insurance behemoth is likely to announce its first-ever bonus issue of shares tomorrow, following its board meeting. The state-run company had announced last week that its board of directors will hold a meeting to consider and recommend its first-ever bonus issue of shares. Maruti Suzuki Car market leader Live Events HUL Unilever global CEO Fernando Fernandez said the biggest priority for India chief ...

The pharmaceutical sector has a reputation for offering high-growth opportunities, but is also known for being risky. However, there's more to that sector than meets the eye. There are pharmaceutical companies that can fit into a value investor's portfolio. Broadly speaking, these companies look undervalued, with high dividend yields and the ability to generate steady revenue. A company that checks all three of those boxes at this moment is Bristol Myers Squibb (BMY 1.43%). Why Bristol Myers Squibb looks li ...

公司核心事件与财务影响 - 合作伙伴Neurocrine Biosciences已启动并完成了NBI-1117570在成人精神分裂症患者中的二期临床研究首例患者给药 [1] - 作为结果，公司将根据协议从Neurocrine获得2250万美元的里程碑付款，该款项将在2026财年第一季度确认为收入 [1][6] 产品管线与临床进展 - NBI-1117570是一种研究性口服双重毒蕈碱M1/M4受体激动剂，由公司的NxWave™药物发现平台发现 [1][3] - 该化合物是Neurocrine毒蕈碱激动剂产品组合中第二个进入二期临床试验的NxWave™设计化合物 [2] - 二期研究是一项双盲、安慰剂对照试验，旨在评估NBI-1117570在需要住院治疗的精神分裂症成人患者中的疗效、安全性和耐受性，预计招募约120名患者 [2] - 主要终点是阳性和阴性症状量表总分相对于基线的变化，关键的次要终点是治疗中出现的不良事件 [2] 目标疾病与市场概况 - 精神分裂症是一种严重且复杂的综合征，世界卫生组织估计该疾病影响全球约2400万人 [4] - 仅在美国，精神分裂症相关的年度成本估计超过1500亿美元，该疾病是全球致残的主要原因之一 [4] - 传统的治疗方法依赖于抗精神病药物，可能带来相当大的短期和长期健康影响，存在显著的未满足医疗需求 [2][4] 公司技术与合作模式 - 公司是一家技术驱动的生物制药公司，致力于为日本及全球未满足需求的患者寻找新的专科药物 [5] - 公司拥有独特的NxWave™ GPCR结构药物发现平台，并利用该平台与领先的制药和生物技术公司合作推进广泛的内部和合作研发管线 [5] - Neurocrine Biosciences从公司获得了开发和商业化NBI-1117570的权利 [3] - 公司已在日本建立了新一代的商业业务，以开发和商业化创新药物，并服务于更广泛的亚太地区市场 [5]

Oh man, you know what? I should have pulled the trigger on Regeneron when I sat down with them at the JPMorgan conference. I realized that the Charitable Trust should have owned it. It would've a much better, really much better drug stock than the others that we have, with the exception of Eli Lilly. While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock tha ...

Seralutinib showed a placebo-adjusted 6MWD improvement of 13.3 meters in Week 24, along with stronger signals in certain subgroups. However, the study failed to meet its prespecified alpha threshold. Additionally, Gossamer Bio, Inc. (NASDAQ:GOSS) halted enrollment in PH-ILD's Phase 3 SERANATA study and reported $136.9 million in cash, cash equivalents, and marketable securities as of the end of 2025, with the expectation that it will fund operations into Q1 of 2027. Gossamer Bio, Inc. (NASDAQ:GOSS) is a pha ...

公司评级与目标价调整 - 2026年4月9日 美国银行将辉瑞目标价从27美元下调至26美元并维持中性评级 此次调整是其一季度大型制药及中小型生物制药公司业绩预览更新的一部分[1][6] - 2026年3月24日 古根海姆将辉瑞目标价从35美元上调至36美元并维持买入评级 上调理由基于其药物mevrometostat预计在2026年下半年获得的三期数据 并指出试验结果可能带来的上行潜力[3] 法律与商业合同进展 - 2026年4月1日 比利时法院命令波兰和罗马尼亚接受并支付价值19亿欧元的辉瑞新冠疫苗 驳回了其不遵守欧盟委员会供应合同的论点 其中波兰需接收价值13亿欧元的剂量 罗马尼亚需接收价值6亿欧元的剂量[2] 研发管线进展 - 2026年3月23日 辉瑞与Valneva报告了莱姆病疫苗候选药物的三期VALOR试验结果 两项分析显示疫苗效力分别为73.2%和74.8% 由于病例数较少未达到第一个预设统计学标准 但公司计划提交监管申请[4] 公司概况与市场观点 - 辉瑞是一家在全球范围内开发和商业化生物制药产品的公司[4] - 有市场观点将辉瑞列为当前值得买入的8只廉价大盘股之一[1] - 另有市场观点认为 尽管辉瑞具备投资潜力 但某些人工智能股票可能提供更大的上行潜力和更小的下行风险[5]

Disclosure: None. Follow Insider Monkey on Google News. On the same day, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced FDA approval of Ponlimsi as a biosimilar to Prolia. The company said the approval covers all indications of the reference product, including treatment of postmenopausal women with osteoporosis at high risk for fracture, supported by data showing comparable efficacy, safety, and immunogenicity. Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops and markets generic and ...

Investors are hyper-focused on what artificial intelligence (AI) will do to the economy. But what if the bigger disruptors -- at least for consumers -- are the revolutionary weight-loss drugs? Revenue for these GLP-1 drugs is actually higher than that of the AI labs at OpenAI and Anthropic, with stocks such as Eli Lilly soaring as a result. Restaurants are currently going through a rough period in the U.S., and some theorize that this is due to the growing use of weight-loss drugs. For example, Chipotle Mex ...

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its ...